← Leaderboards
Josef Vagner
University Of Arizona
$2,217,739
Attributed
$8,329,407
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2011–23$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$8,329,407 · 4
By mechanism
R01$4,456,396 · 2
R42$3,433,831 · 1
R56$439,180 · 1
Top collaborators
- Scott Boitano14 shared
- Theodore J Price12 shared
- Gregory O Dussor7 shared
- Monica Kraft2 shared
- Julie Gunnells Ledford2 shared
Most similar at University Of Arizona
Same institution · by research overlap
- Tally Marie Milnes$6,839,334
- Xinxin Ding$16,563,001
Others in their field
Top investigators on “Peptide Hydrolases”
- John Damon Chodera · Sloan-Kettering Inst Can Research$39,488,414
- David Heimbrook · Leidos Biomedical Research, Inc.$26,054,235
- Martin Friedlander · Scripps Research Institute$17,515,314
- Celia A. Schiffer · Univ Of Massachusetts Med Sch Worcester$17,146,142
- Charles Scott Craik · University Of California, San Francisco$15,872,050
- J. Edwin Blalock · University Of Alabama At Birmingham$15,690,917
Research focus
Peptide HydrolasesNovel TherapeuticsValidationPre-ClinicalMouse ModelPharmaceutical PreparationsLeadPeptidomimeticsPharmacologyPathologyNociceptorsPlayNervous System DisorderSignal PathwayMolecularDrug DiscoveryNociceptionLigandsPainPathway InteractionsLabelAgonistPar-2 ReceptorCell Analyzer
Grant awards (14)
Development of SP-A Derived Peptidomimetics for the Treatment of Asthma - Phase II$1,478,237
R42 · FY2023 · HL
Development of SP-A Derived Peptidomimetics for the Treatment of Asthma - Phase II$1,955,594
R42 · FY2022 · HL
Protease Activated Receptor Type 2 Targeting for Migraine Pain$481,084
R01 · FY2021 · NS
Protease Activated Receptor Type 2 Targeting for Migraine Pain$481,084
R01 · FY2020 · NS
Protease Activated Receptor Type 2 Targeting for Migraine Pain$481,084
R01 · FY2019 · NS
Protease Activated Receptor Type 2 Targeting for Migraine Pain$512,010
R01 · FY2018 · NS
Protease Activated Receptor Type 2 Targeting for Migraine Pain$382,151
R01 · FY2018 · NS
Protease Activated Receptor Type 2 Targeting for Migraine Pain$494,334
R01 · FY2017 · NS
Protease Activated Receptor Type 2 Targeting for Migraine Pain$439,180
R56 · FY2016 · NS
PAR2 targeted drug discovery for the treatment of pain$327,669
R01 · FY2015 · NS
PAR2 targeted drug discovery for the treatment of pain$324,499
R01 · FY2014 · NS
PAR2 targeted drug discovery for the treatment of pain$316,408
R01 · FY2013 · NS
PAR2 targeted drug discovery for the treatment of pain$327,987
R01 · FY2012 · NS
PAR2 targeted drug discovery for the treatment of pain$328,086
R01 · FY2011 · NS